1. Which of the following accurately reflects preferred, category 1 antibody-based regimens in the setting of RRMM as noted in clinical practice guidelines in the myeloma setting (as of April 2021)?

2. You are managing a man aged 56 years with newly diagnosed symptomatic MM and a PS of 0-1. Assume the patient is transplant eligible and receives RVd induction followed by ASCT and maintenance lenalidomide. Subsequently, the patient relapses and testing confirms renal impairment (eGFR 40 mL/min). In consultation with colleagues on the healthcare team, how would you manage this patient?

3. In collaboration with colleagues on the healthcare team, you are managing a patient aged 73 years with MM who has relapsed after multiple prior therapies (including proteasome inhibitor–based, immunomodulatory-based, and antibody-based regimens). The patient is a candidate for subsequent therapy with the BCMA ADC belantamab mafodotin. How would you develop pretherapy, team-wide protocols for this patient?

4. You are planning to recommend the use of the novel BCMA CAR-T construct idecabtagene vicleucel (ide-cel) for the management of a heavily pretreated patient with RRMM. How would you prepare the healthcare staff to address important preinfusion and safety considerations before the patient starts therapy?

5. Which statement is true regarding PFS outcomes from the phase 3 IKEMA trial testing isatuximab-Kd vs Kd in the setting of RRMM?

« Return to Activity